Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma

@article{Hyeon2013ExpressionOF,
  title={Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma},
  author={Jiyeon Hyeon and Soomin Ahn and Jae Jun Lee and Dae-Hyun Song and Cheol Keun Park},
  journal={Digestive Diseases and Sciences},
  year={2013},
  volume={58},
  pages={1916-1922}
}
BackgroundFibroblast growth factor 19 (FGF19)-mediated activation of mitogen-activated protein kinase and the β-catenin pathway may be involved in the development and progression of hepatocellular carcinoma. This study aimed to elucidate the prognostic significance of FGF19 protein expression in hepatocellular carcinoma patients.MethodsBy immunohistochemistry, we investigated the expression of FGF19 protein in tumor tissue from 281 hepatocellular carcinoma patients who underwent curative… 
Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma
TLDR
This is the first study to elucidate FGF19/FGFR4 signaling in favor of HCC cells developing as indicated by increased EpCAM within the carcinogenesis sequence from fatty liver to hepatocellular carcinoma.
Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid Cancer
TLDR
The data revealed that the increased expression of FGF19 might be involved in the malignant behaviors of thyroid cancer, highlighting its potential as a molecular marker for early diagnosis and as a possible target for therapeutic intervention of this disease.
Upregulation of FGF 19 in lung adenocarcinoma and predicts poor prognosis
TLDR
Analysis of the expression of FGF19 in LAC tissues and corresponding normal tissues suggested that up-regulation of F GF19 might potentially be an effective therapeutic approach for LAC.
Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis
TLDR
Interference with FGF15/19-FGFR4 signaling represents a novel strategy in HCC therapy and selection of candidate patients based on tumoral FGF19-GFFR4/KLB levels as biomarkers may result in increased efficacy of FGFR4-targeted drugs.
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
TLDR
FGF19 showed higher sensitivity for the detection of small HCC than those of existing markers and may help improve the prognosis in HCC patients owing to its resourceful use in various aspects of HCC management and treatment.
Lack of relationships between FGF19 staining pattern, lymph node metastasis and locally invasive characteristics of the tumor in colorectal cancers.
TLDR
No evidence of significant statistically correlation was found between FGF 19 staining pattern and serosal, perineural, vascular invasion, lymph node involvement and degree of differentiation in colorectal cancers patients undergoing surgery with no evidence of preoperative radiological distant metastasis.
Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma
TLDR
It is suggested that HCC patients with high FGFR2/3 or FGF19/FGFR4 expressing tumors might benefit from a combination infigratinib/FGF401, and its evaluation in clinical trials is supported.
Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study
TLDR
Investigating the prognostic significance of FGF19 amplification in a large cohort of 989 HCC patients using fluorescence in situ hybridization (FISH), which has a high degree of specificity, indicates that FGF 19 amplification represents a unique molecular subtype associated with poor prognostic characteristics, which supports the hypothesis that the F GF19-FGFR4 signaling pathway plays an important role in hepatocarcinogenesis.
Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways
TLDR
Results indicate that the inflammatory response during fibrogenesis increases FGF21 levels and suppresses β-Klotho via the NF-κB and JNK pathway, and likely protects hepatocytes from hepatic inflammation and fibrosis.
FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
TLDR
FGF401 synergistically acted with the microtubule-depolymerizing drug vinorelbine to further suppress tumor growth, promote apoptosis, and prolong the OS of mice bearing high FGF19 tumors, with no evidence of increased toxicity.
...
...

References

SHOWING 1-10 OF 26 REFERENCES
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
TLDR
FGF19 was significantly overexpressed in HCCs as compared with corresponding noncancerous liver tissue and univariate and multivariate analyses revealed that the tumor FGF19 mRNA expression was an independent prognostic factor for overall and disease-free survival.
Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature
TLDR
Molecular markers (biomarkers) for hepatocellular carcinoma (HCC) metastasis and recurrence could provide additional information to that gained from traditional histopathological features, as understanding of tumor biology deepens.
Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
TLDR
FGF19/FGFR4 cross-talk with beta-catenin and that pathway intervention reduces tumor growth is highlighted and wild-type beta-Catenin is accessible for modulation.
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
TLDR
The feasibility of genomewide expression profiling of formalin-fixed, paraffin-embedded tissues is demonstrated and it is shown that a reproducible gene-expression signature correlated with survival is present in liver tissue adjacent to the tumor in patients with hepatocellular carcinoma.
A Gene Expression Profile for Vascular Invasion can Predict the Recurrence After Resection of Hepatocellular Carcinoma: a Microarray Approach
TLDR
Using the 14-gene expression profile extracted from microarrays based on the presence of VI can effectively predict recurrence after HCC resection, which might facilitate “personalized medicine” for HCC patients after surgical resection.
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
TLDR
It is reported that fibroblast growth factor 19 and its cognate receptor FGF receptor 4 are coexpressed in primary human liver, lung and colon tumors and in a subset of human colon cancer cell lines, and an anti-FGF19 monoclonal antibody is developed that selectively blocks the interaction of FGF19 with FGFR4.
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
TLDR
It is demonstrated that FGFR4 is required for hepatocarcinogenesis; the progeny of FGF19 transgenic mice, which have previously been shown to develop HCCs, bred withFGFR4 knockout mice fail to develop liver tumors and are suggested to be an important and novel therapeutic target in treating this disease.
...
...